Abstract
GlobeImmune’s Tarmogen® immunotherapy platform utilizes recombinant Saccharomyces cerevisiae yeast as a vaccine vector to deliver heterologous antigens for activation of disease-specific, targeted cellular immunity. The vaccines elicit immune-mediated killing of target cells expressing viral and cancer antigens in vivo via a CD8+ CTL-mediated mechanism. Tarmogens are not neutralized by host immune responses and can be administered repeatedly to boost antigen-specific immunity. Production of the vaccines yields stable off-the-shelf products that avoid the need for patient-specific manufacturing found with other immunotherapeutic approaches. Tarmogens for the treatment of chronic hepatitis B and C and various cancers were well tolerated and immunogenic in phase 1 and 2 clinical trials encompassing >600 subjects. The platform is being widely utilized in basic vaccine research and the most rapid path to success in these endeavors follows from optimal immunoassay selection and execution. This chapter provides detailed methods for the construction and preclinical immunogenicity testing of yeast-based immunotherapeutic products to support the rapid and efficient use of this versatile technology.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Stubbs A, Martin KS, Coeshott C et al (2001) Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7:625–629
Cereda V, Vergati M, Huen N-Y et al (2011) Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine 29:4992–4999
Cheng S-C, van de Veerdonk FL, Lenardon M et al (2011) The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol 90:357–366
Gaggar A, Coeshott C, Apelian D et al (2014) Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 32:4925–4931
Wansley EK, Chakraborty M, Hance KW et al (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14:4316–4325
Ardiani A, Farsaci B, Rogers CJ et al (2013) Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 19:6205–6218
Ardiani A, Gameiro SR, Palena C et al (2014) Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Res 74:1945–1957
King TH, Kemmler CB, Guo Z et al (2014) A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One 9(7):e101904
Haller A, Lauer GM, King TH et al (2007) Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25:1452–1463
Wu H, Ng BSH, Thibault G (2014) Endoplasmic reticulum stress response in yeast and humans. Biosci Rep 34:321–330
Shen MWY, Fang F, Sandmeyer S et al (2012) Development and characterization of a vector set with regulated promoters for systematic metabolic engineering in Saccharomyces cerevisiae. Yeast 29:495–503
Nakagawa S, Niimura Y, Gojobori T et al (2008) Diversity of preferred nucleotide sequences around the translation initiation codon in eukaryote genomes. Nucleic Acids Res 36:861–871
Schaffner W, Weissmann C (1973) A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal Biochem 56:502–514
Hamilton DH, Litzinger MT, Jales A et al (2013) Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 4:1777–1790
Betts MR, Brenchley JM, Price DA et al (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78
Andersson HA, Barry MA (2004) Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther 10:432–446
Liard C, Munier S, Joulin-Giet A et al (2011) Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 132:615–625
Acknowledgements
We thank Kirk Christoffersen and Dr. Angela Sebor for critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
King, T.H., Guo, Z., Hermreck, M., Bellgrau, D., Rodell, T.C. (2016). Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1404. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-3389-1_35
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3389-1_35
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-3388-4
Online ISBN: 978-1-4939-3389-1
eBook Packages: Springer Protocols